Literature DB >> 29802442

[Influence of rocuronium dose on the effectiveness of mask ventilation : A prospective, randomized clinical trial].

M Hellmund1, J Bajorat1, S Machmüller1, M Sauer1, A Zitzmann1, D A Reuter1, T Mencke2.   

Abstract

BACKGROUND: Mask ventilation could improve after administration of muscle relaxants if there is a functional obstruction of the airway, such as laryngospasm, vocal cord closure or opioid-induced muscle rigidity. On the other hand, muscle relaxants could worsen mask ventilation because they induce upper airway collapse; however, clinical studies showed that rocuronium (Roc) improved mask ventilation or it remained unchanged. In most cases Roc 0.06 mg/kgBW was used.
OBJECTIVE: The optimal dose of Roc has not been studied; therefore, we studied the quality of mask ventilation with three different doses of Roc (0.3, 0.6 and 0.9 mg/kgBW) and compared them with a control group receiving saline.
MATERIAL AND METHODS: In this prospective clinical trial 200 patients were randomized into 4 groups: NaCl (saline), Roc03 (Roc 0.3 mg/kgBW), Roc06 (Roc 0.6 mg/kgBW) and Roc09 (Roc 0.9 mg/kgBW). Mask ventilation was performed to reach a tidal volume (TV) of >5.0 ml/kgBW; maximum ventilation peak pressure (ppeak) was limited to 25 mbar. If this TV was not reached, mask ventilation was improved by better mask position, head position or/and usage of a Guedel tube (oropharyngeal airway). During mask ventilation ppeak and TV were recorded and the quality of mask ventilation was assessed with the Han and Warters scores. The quality of mask ventilation between the four groups was compared for all patients and a subgroup analysis was performed for patients of the study groups, who had to be ventilated with a Guedel tube and for obese patients (body mass index ≥26 kg/m2). A sample size calculation revealed that at least 38 patients were necessary for each group to detect a statistically significant difference between groups; it was assumed that Roc improved the efficacy of mask ventilation by 20% compared to saline (α = 0.05, 1-β = 0.8).
RESULTS: The administration of Roc significantly improved the TV/ppeak ratio compared to saline (p = 0.04); however, this effect was irrespective of the dose. In patients who were ventilated with the Guedel tube the TV/ppeak ratio increased after Roc03 (p ≤ 0.01) and after Roc06 (p < 0.02) compared to the saline group. In obese patients who were ventilated with the Guedel tube the TV/ppeak ratio increased after Roc03 (p ≤ 0.01), after Roc06 (p = 0.03) and after Roc09 (p = 0.02) compared to the saline group. There were no significant differences between the Roc groups; however, the effect was more pronounced in the Roc03 patients compared to the other Roc groups. The Han and Warters scores were not significantly different between the Roc groups and the saline group.
CONCLUSION: The efficacy of mask ventilation was equal or improved after administration of Roc but did not become worse. Patients who were ventilated with a Guedel tube had higher TV/ppeak ratios after Roc03 and Roc06 compared to saline. Higher dosages (>Roc06), however, had no advantages concerning quality of mask ventilation. In obese patients who had to be ventilated with a Guedel tube, Roc also improved the efficacy of mask ventilation. We conclude that administration of Roc is effective in improving mask ventilation and this effect was seen after 30-60 s even after Roc03.

Entities:  

Keywords:  Airway; Complications; Obesity; Rocuronium; Tidal volume

Mesh:

Substances:

Year:  2018        PMID: 29802442     DOI: 10.1007/s00101-018-0454-1

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  27 in total

Review 1.  Perioperative pharmacology in morbid obesity.

Authors:  Hendrikus J m Lemmens
Journal:  Curr Opin Anaesthesiol       Date:  2010-08       Impact factor: 2.706

2.  The effect of neuromuscular blockade on the efficiency of mask ventilation of the lungs.

Authors:  M W P Goodwin; J J Pandit; K Hames; M Popat; S M Yentis
Journal:  Anaesthesia       Date:  2003-01       Impact factor: 6.955

3.  Impossible mask ventilation.

Authors:  Ian Calder
Journal:  Anesthesiology       Date:  2007-07       Impact factor: 7.892

4.  Could 'safe practice' be compromising safe practice? Should anaesthetists have to demonstrate that face mask ventilation is possible before giving a neuromuscular blocker?

Authors:  I Calder; S M Yentis
Journal:  Anaesthesia       Date:  2008-02       Impact factor: 6.955

5.  Avoidance of neuromuscular blocking agents may increase the risk of difficult tracheal intubation: a cohort study of 103,812 consecutive adult patients recorded in the Danish Anaesthesia Database.

Authors:  L H Lundstrøm; A M Møller; C Rosenstock; G Astrup; M R Gätke; J Wetterslev
Journal:  Br J Anaesth       Date:  2009-05-20       Impact factor: 9.166

6.  The effect of neuromuscular blockade on mask ventilation.

Authors:  R D Warters; T A Szabo; F G Spinale; S M DeSantis; J G Reves
Journal:  Anaesthesia       Date:  2011-01-25       Impact factor: 6.955

7.  Mask Ventilation during Induction of General Anesthesia: Influences of Obstructive Sleep Apnea.

Authors:  Shin Sato; Makoto Hasegawa; Megumi Okuyama; Junko Okazaki; Yuji Kitamura; Yumi Sato; Teruhiko Ishikawa; Yasunori Sato; Shiroh Isono
Journal:  Anesthesiology       Date:  2017-01       Impact factor: 7.892

8.  Prediction and outcomes of impossible mask ventilation: a review of 50,000 anesthetics.

Authors:  Sachin Kheterpal; Lizabeth Martin; Amy M Shanks; Kevin K Tremper
Journal:  Anesthesiology       Date:  2009-04       Impact factor: 7.892

9.  Effects of muscle relaxants on mask ventilation in anesthetized persons with normal upper airway anatomy.

Authors:  Aya Ikeda; Shiroh Isono; Yumi Sato; Hisanori Yogo; Jiro Sato; Teruhiko Ishikawa; Takashi Nishino
Journal:  Anesthesiology       Date:  2012-09       Impact factor: 7.892

10.  The Myth of Rescue Reversal in "Can't Intubate, Can't Ventilate" Scenarios.

Authors:  Mohamed Naguib; Lara Brewer; Cristen LaPierre; Aaron F Kopman; Ken B Johnson
Journal:  Anesth Analg       Date:  2016-07       Impact factor: 5.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.